Premium
Should treatment of ALK‐positive anaplastic large cell lymphoma be stratified according to minimal residual disease?
Author(s) -
Rigaud Charlotte,
Abbas Rachid,
Grand David,
MinardColin Véronique,
Aladjidi Nathalie,
Buchbinder Nimrod,
Garnier Nathalie,
Plat Geneviève,
Couec MarieLaure,
Duplan Mylène,
Lambilliotte Anne,
Schmitt Claudine,
Leblanc Thierry,
Lamant Laurence,
Brugières Laurence
Publication year - 2021
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28982
Subject(s) - medicine , anaplastic lymphoma kinase , minimal residual disease , anaplastic large cell lymphoma , oncology , lymphoma , cohort , chemotherapy , leukemia , malignant pleural effusion , lung cancer
In anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma (ALK+ ALCL), positive minimal residual disease (MRD+) after the first chemotherapy course was proven of strong prognostic significance. We aimed to validate these results in 138 French patients. Eighty‐seven patients had a detectable minimal disseminated disease at diagnosis (MDD+). Early MRD assessment was performed in 33 of 87 patients and was positive in 18 and negative in 15 (MRD−). Three‐year progression‐free survival was significantly correlated with the MDD/MRD status: 81.1% in MDD−, 69.6% in MDD+/MRD−, and 15.2% in MDD+/MRD+ patients. In conclusion, we confirmed on an independent cohort that the MDD/MRD status has strong prognosis significance in ALK+ ALCL.